-  INCLUSION CRITERIA:

          -  Patients must have histologically or cytologically confirmed diagnosis of colorectal
             adenocarcinoma, confirmed by the Laboratory of Pathology, NCI.

          -  Patients must have measurable liver metastatic disease.

          -  Patients must have progressed on, been intolerant of or have residual disease after
             oxaliplatin- or irinotecan-containing, fluorouracil-based, chemotherapeutic regimen.

          -  Age greater than or equal to 18 years.

          -  ECOG performance status less than or equal to 1

          -  Patients must have adequate organ and marrow function as defined below:

               -  leukocytes > 3,000/mcL

               -  absolute neutrophil count > 1,500/mcL

               -  platelets > 90,000/mcL

               -  total bilirubin < 1.5 X institutional upper limit of normal

               -  AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal

               -  creatinine within normal institutional limits OR eGFR within normal as predicted
                  by the CKD-EPI equation > 60 mL/min/1.73 m2.

          -  The hepatic artery infusion pump chemotherapy has potential teratogenic and/or
             abortifacient effects. For this reason, women of child-bearing potential and men must
             agree to use adequate contraception (hormonal or barrier method of birth control;
             abstinence) prior to study entry, for the duration of study participation and for 3
             months after completion of study treatment. Should a woman become pregnant or suspect
             she is pregnant while she or her partner is participating in this study, she should
             inform her treating physician immediately.

          -  Arterial anatomy on CT angiogram amenable to placement of the HAIP.

          -  Ability of subject to understand and the willingness to sign a written informed
             consent document.

          -  HIV-positive patients may be considered for this study only after consultation with an
             HIV trained physician.

          -  Patients must agree to co-enroll on the Surgical Oncology Program s tissue collection
             protocol 13C0176, 'Tumor, Normal Tissue and Specimens from Patients Undergoing
             Evaluation or Surgical Resection of Solid Tumors'

        EXCLUSION CRITERIA:

          -  Patients with liver metastases amenable to resection to No Evidence of Disease (NED)
             in one stage.

          -  Patients who are receiving any other investigational agents.

          -  Patients with incontrovertible radiographic evidence of disease outside of the
             colon/rectum (primary) and liver given unlikelihood of benefit from liver-directed
             therapy.

        Note: The exception to this exclusion is patients with fewer than five lung lesions greater
        than 1 cm that have not increased in size by more than 10% over a 4-month period of time,
        and are amenable to resection should subsequent problematic growth occur. Lesions less than
        1 cm are indeterminant as far as etiology is concerned and will be ignored. Patients with
        liver metastases and oligometastatic lung lesions (we define oligometastatic as less than 5
        amen ble to thoracoscopic removal) are still likely to benefit from liver directed therapy.

          -  Patients who have undergone extra-hepatic metastasectomy and have a documented
             disease-free interval less than or equal to 4 months.

          -  MSI-high patients who need to be treated with a check-point inhibitors

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements. This also includes any condition, including the presence of
             laboratory abnormalities, which in the opinion of the Principal Investigator places
             the subject at unacceptable risk if they were to participate in the study or confounds
             the ability to interpret data from the study.

          -  Active concurrent malignancies within the last five years other than colorectal
             primary except basal cell skin carcinoma and thyroid carcinoma.

          -  Prior radiation to liver.

          -  Pregnant women are excluded from this study because of the potential for teratogenic
             or abortifacient effects of the HAIP chemotherapy. Because there is an unknown but
             potential risk for adverse events in nursing infants secondary to treatment of the
             mother with HAIP, breastfeeding should be discontinued if the mother is treated. These
             potential risks may also apply to other agents used in this study.

          -  Patients with active Hepatitis B or C infection because of the potential for increased
             liver toxicity given the damaging effects of the virus.

          -  History of allergic reactions attributed to compounds of similar chemical composition
             to FUDR or heparin.